Non-invasive diagnosis of bladder cancer: New molecular markers and future perspectives;Diagnóstico no invasivo en cáncer de vejiga: Nuevos marcadores moleculares y futuras perspectivas

Archivos Espanoles de Urologia

Volumn 66, Issue 5, 2013, Pages 487-494

  Musquera, Mireia ^a   Mengual, Lourdes ^a   Ribal, María José ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Biomarkers; Bladder cancer; Molecular biology; Non invasive diagnostic

Indexed keywords

BIOLOGICAL MARKER; NUCLEAR MATRIX PROTEIN 22; NUCLEAR PROTEIN; TUMOR ANTIGEN; TUMOR MARKER; TUMOR PROTEIN;

ANIMAL; BLADDER TUMOR; FLUORESCENCE IN SITU HYBRIDIZATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; REVIEW;

ANIMALS; ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; NEOPLASM PROTEINS; NUCLEAR PROTEINS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER NEOPLASMS;

EID: 84879155511     PISSN: 00040614     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (48)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. CA Cancer J Clin 2010;60:227-300.
2. Stenzl A, Cowan NC, De Santis M, Jakse G, Kuczyk MA, Merseburger AS, et al. The Updated EAU Guidelines on Muscle-Invasive and Metastatic Bladder Cancer. European Urology. 2009;55(4):815-825.
3. Grossman HB, Soloway M, Messing E, Katz G, Stein B, Kassabian V, et al. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA: The Journal of the American Medical Association. 2006; 18;295(3):299-305.
4. Glas As, Roos D, Deutekom M, Zwinderman Ah, Bossuyt PM, Kurth KH. Tumor markers in the diagnosis of primary bladder cancer. A systematic review. JURO. 2003;169(6):1975-1982.
5. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP, et al. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. In: Urology. 2005. p. 35-63.
6. Mowatt G, Zhu S, Kilonzo M, Boachie C, Fraser C, Griffiths TRL, et al. Systematic review of the clinical effectiveness and cost effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technol. Assess, 2010; 14, 1-331.
7. Tritschler S, Sommer ML, Straub J, Hocaoglu Y, Tilki D, Strittmatter F, et al. Urinary cytology in era of fluorescence endoscopy: redefining the role of an established method with a new reference standard. Urol, 2010; 76, 677-681
8. Sylvester RJ, van der Meijden APM, Oosterlinck W, et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol, 2006;49:466-77.
9. Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, Seeilg SA, et al. The development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J. Mol. Diagn, 2000; 2, 116-123.
10. Friedrich MG, Toma MI, Hellstern A, Pantel K, Weisenberger DJ, Noldus J, et al. Comparison of multitarget fluorescence in situ hybridization in urine with other noninvasive tests for detecting bladder cancer. BJU Int, 2003; 92, 911-914.
11. Sarsody MF, Schellhammer P, Bokinsky G, Kahn P, Chao R, Yore L, et al. Clinical evaluation of a multi-target fluorescent in situ hybridization assay for detection of bladder cancer. J. Urol, 2002; 168, 1950-1954.
12. Grossman HB, Messing E, Soloway M, Tomera K, Katz G, Berger Y, et al. Detection of bladder cancer using a point of care proteomic assay. JAMA, 2005; 293, 810-816.
13. Babjuk M, Kostirova M, Mudra K, et al. Qualitative and quantitative detection of urinary human complement factor H-related proteín(BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBC IRMA) as markers for transitional cell carcinoma of the bladder. Eur Urol, 2002;41:34 -9.
14. Pfister C, Chautard D, Devonec M, et al. Immunocyt test improves the diagnostic accuracy of urinary cytology: Results of a French multicenter study. J Urol, 2003;169:921- 4.
15. G.Mowatt, S. Zhu, M. Kilonzo et al. Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer. Health Technology Assessment, vol. 14, no. 4, pp. 1-331, 2010.
16. Van Rhijm BWG, van der Poel HG, and van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur. Urol, 2005; 47, 736-748.
17. Van Rhijn BWG, Van der Poel HG, Van der Kwast ThH. Urine Markers for bladder Cancer Srveillance. A systematic review. Eur Urol, 2005; 47:736-48.
18. Frigerio S, Padberg BC, Strebel RT, Lenggenhager DM, Messthaler A, Abdou MT, et al. Improved detection of bladder carcinoma cells in voided urine by standardized microsatellite analysis. Int. J. Cancer, 2007; 121, 329-338.
19. Seripa D, Parrella P, Gallucci M, Gravina C, Papa S, Fortunato P, et al. Sensitive detection of transitional cell carcinoma of the bladder by microsatellite analysis of cells exfoliated in urine. Int. J. Cancer, 2001; 95, 364-369.
20. Sen S, Zhou H, Zhang RD, et al. Amplification/overexpression of a mitotic kinase gene in human bladder cancer . J Natl Cancer Inst, 2002; 94 (17): 1320 - 1329 .
21. Park HS, Park WS, Bondaruk J, et al. Quantitation of Aurora kinase A gene copy number in urine sediments and bladder cancer detection. J Natl Cancer Inst, 2008; 100:1401-11.
22. S. Vinci, G. Giannarini, C. Selli et al, Quantitative methylation analysis of BCL2, hTERT, and DAPK promoters in urine sediment for the detection of non-muscle-invasive urothelial carcinoma of the bladder: a prospective, two-center validation study. Urologic Oncology, vol. 29, no. 2, pp. 150-156, 2011.
23. M. O. Hoque, S. Begum, M. Brait et al. Tissue inhibitor of metalloproteinases-3 promotermethylation is an independent prognostic factor for bladder cancer. Journal of Urol, 2008; 179, (2):743-747.
24. W. Chung, J. Bondaruk, J. Jelinek et al. Detection of bladder cancer using novel DNA methylation biomarkers in urine sediments. Cancer Epidemiology Biomarkers and Prevention, 2011; 20(7): 1483-1491.
25. I. Renard, S. Joniau, B. van Cleynenbreugel et al. Identification and validation of the methylated TWIST1 and NID2 genes through real-time methylation-specific polymerase chain reaction assays for the noninvasive detection of primary bladder cancer in urine samples. European Urology, 2010; 58(1): 96-104.
26. Heller MJ. DNA microarray technology: devices, systems, and applications. Annu. Rev. Biomed. Eng. 2002;4:129-153.
27. Sanchez-Carbayo M, Cordon-Cardo C. Applications of array technology: identification of molecular targets in bladder cancer. Br J Cancer. 2003; 15;89(12):2172-2177
28. Mengual L, Burset M, Ars E, Lozano JJ, Villavicencio H, Ribal MJ, et al. DNA Microarray Expression Profiling of Bladder Cancer Allows Identification of Noninvasive Diagnostic Markers. JURO. 2009. 1;182(2):741-748.
29. Mengual L, Burset M, Ribal MJ, Ars E, Marin-Aguilera M, Fernandez M, et al. Gene Expression Signature in Urine for Diagnosing and Assessing Aggressiveness of Bladder Urothelial Carcinoma. Clinical Cancer Research. 2010. 28;16(9):2624-2633.
30. Yamada Y, Enokida H, Kojima S, Kawakami K, Chiyomaru T, Tatarano S, et al. MiR-96 and miR-183 detection in urine serve as potential tumor markers of urothelial carcinoma: correlation with stage and grade, and comparison with urinary cytology. Cancer Sci. 2011;102(3):522-9. doi: 10.1111/j.1349-7006.2010. 01816.x. Epub 2010 Dec 19.
31. Puerta-Gil P, García-Baquero R, Jia AY, Ocaña S, Alvarez-Múgica M, Alvarez-Ossorio JL, et al. miR-143, miR-222, and miR-452 are useful as tumor stratification and noninvasive diagnostic biomarkers for bladder cancer. Am J Pathol. 2012 May;180(5):1808-15. Epub 2012 Mar 15.
32. Wang Y, Luo H, Li Y, Chen T, Wu S, Yang L. hsa-miR-96 up-regulates MAP4K1 and IRS1 and may function as a promising diagnostic marker in human bladder urothelial carcinomas. Mol Med Report. 2012 Jan;5(1):260-5. doi: 10.3892/mmr.2011.621. Epub 2011 Oct 11.
33. Yates DR, Rehman I, Abbod MF, et al. Promoter hypermethylation identifies progression risk in bladder cancer. Clin Cancer Res 2007; 13:2046-53.
34. Catto JWF, Abbod MF, Wild PJ, et al. The application of artificial intelligence to microarray data: identification of a novel gene signature to identify bladder cancer progression. Eur Urol 2010;57:398-406
35. Pode D, Golijanin D, Sherman Y, Lebensart P, and Shapiro, A. Immunostaining of Lewis X in cells from voided urine, cytopathology, and ultrasound for noninvasive detection of bladder tumors. J. Urol, 1998; 159, 389-393.
36. Ramakumar S, Bhuiyan J, Besse JA, Roberts SG, Wollan PC, Blute ML, et al. Comparison of screening methods in the detection of bladder cancer. J. Urol, 1999; 161, 388-394.
37. Sanchini MA, Gunelli R, Nanni O, Bravaccini S, Fabbri C, Sermasi A, et al. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA, 2005; 294, 2052-2056.
38. Lokeshwar VB, Obek C, Pham HT, Wei D, Young MJ, Duncan, RC, et al. Urinary hyaluronic acid and hyaluronidase: markers for bladder cancer detection and evaluation of grade. J. Urol, 2000; 163, 348-356.
39. Van Le TS, Miller R, Barder T, Babjuk M, Potter DM, and Getzenbeg RH. Highly specific urine-based marker of bladder cancer. Urol, 2005; 66, 1256-1260.
40. Myers-Irvin JM, Landsittel D, Getzenberg RH. Use of the novel marker BLCA-1 for the detection of bladder cancer. J Urol, 2005; 174:64-8.
41. Pariente JL, Bordenave L, Michel P, et al. Initial evaluation of CYFRA 21-1 diagnostic performances as a urinary marker in bladder transitional cell carcinoma. J Urol, 1997;158:338-41.
42. Golijanin D, Shapiro A, Pode D. Immunostaining of cytokeratin 20 in cells from voided urine for detection of bladder cancer. J Urol, 2000;164:1922-5.
43. Lin S, Hirschowitz SL, Williams C, et al. Cytokeratin 20 as an immunocytochemical marker for detection of urothelial carcinoma in atypical cytology: Preliminary retrospective study on archived urine slides. Cancer Detect Prev, 2001;25:202-9.
44. Mian C, Lodde M, Haitel A, et al. Comparison of two qualitative assays, the UBC rapid test and the BTA stat test, in the diagnosis of urothelial cell carcinoma of the bladder. Urol, 2000;56:228 -31.
45. Margel D, Pevsner-Fischer M, Baniel J, Yossepowitch O, Cohen IR. Stress proteins and cytokines are urinary biomarkers for diagnosis and staging of bladder cancer. Eur Urol, 2011;59(1):113-9. Epub 2010 Oct 15.
46. Horstmann M, Bontrup H, Hennenlotter J, et al. Clinical experience with survivin as a biomarker for urothelial bladder cancer.World J Urol 2010;28:399-404.
47. Sanchez-Carbayo M, Socci ND, Lozano JJ, Li W, Charytonowicz E, Belbin TJ, et al. Gene discovery in bladder cancer progression using cDNA microarrays. Am J Pathol, 2003; 163:505-516.
48. Datta A, Adelson ME, Mogilevkin Y, Mordechai E, Sidi AA, Trama JP. Oncoprotein DEK as a tissue and urinary biomarker for bladder cancer. BMC Cancer, 2011; 10;11:234.